Bruker Co. (NASDAQ:BRKR) Shares Purchased by Edgestream Partners L.P.

Edgestream Partners L.P. increased its stake in Bruker Co. (NASDAQ:BRKR - Free Report) by 602.8% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund owned 111,805 shares of the medical research company's stock after acquiring an additional 95,897 shares during the period. Edgestream Partners L.P. owned approximately 0.07% of Bruker worth $6,554,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. FMR LLC boosted its holdings in shares of Bruker by 21.4% in the 3rd quarter. FMR LLC now owns 14,306,122 shares of the medical research company's stock valued at $987,981,000 after purchasing an additional 2,521,904 shares during the last quarter. Vaughan Nelson Investment Management L.P. grew its position in Bruker by 140.3% during the fourth quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company's stock valued at $66,930,000 after acquiring an additional 666,617 shares during the period. Point72 DIFC Ltd increased its stake in Bruker by 4,875.9% during the third quarter. Point72 DIFC Ltd now owns 470,171 shares of the medical research company's stock worth $32,470,000 after acquiring an additional 460,722 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Bruker by 1,933.2% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 410,234 shares of the medical research company's stock worth $28,331,000 after purchasing an additional 390,057 shares during the period. Finally, State Street Corp raised its holdings in shares of Bruker by 9.6% in the 3rd quarter. State Street Corp now owns 3,627,300 shares of the medical research company's stock worth $250,501,000 after purchasing an additional 318,808 shares during the period. 79.52% of the stock is currently owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

A number of analysts recently issued reports on the stock. Guggenheim reissued a "buy" rating on shares of Bruker in a research report on Monday, February 24th. UBS Group initiated coverage on shares of Bruker in a research note on Tuesday, December 10th. They issued a "neutral" rating and a $66.00 target price on the stock. Barclays reduced their target price on shares of Bruker from $69.00 to $65.00 and set an "overweight" rating on the stock in a report on Monday, February 10th. Stifel Nicolaus lowered their price target on Bruker from $70.00 to $57.00 and set a "hold" rating for the company in a report on Friday, February 14th. Finally, The Goldman Sachs Group upgraded Bruker from a "sell" rating to a "neutral" rating and set a $60.00 price objective on the stock in a research note on Thursday, December 5th. Six analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $70.50.

Bruker Stock Down 3.9 %

BRKR stock traded down $1.84 during mid-day trading on Tuesday, hitting $45.56. 2,530,365 shares of the company were exchanged, compared to its average volume of 1,262,785. The firm has a fifty day simple moving average of $54.97 and a 200 day simple moving average of $59.00. The company has a market capitalization of $6.91 billion, a PE ratio of 59.95, a price-to-earnings-growth ratio of 2.16 and a beta of 1.18. Bruker Co. has a twelve month low of $44.94 and a twelve month high of $94.86. The company has a current ratio of 1.60, a quick ratio of 0.77 and a debt-to-equity ratio of 1.15.

Bruker (NASDAQ:BRKR - Get Free Report) last released its earnings results on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping analysts' consensus estimates of $0.75 by $0.01. Bruker had a return on equity of 21.01% and a net margin of 3.36%. On average, research analysts forecast that Bruker Co. will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Monday, March 17th will be issued a $0.05 dividend. The ex-dividend date of this dividend is Monday, March 17th. This represents a $0.20 dividend on an annualized basis and a yield of 0.44%. Bruker's dividend payout ratio is currently 26.32%.

Bruker Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.